Ivan Randelovic
Overview
Explore the profile of Ivan Randelovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Svajda L, Randelovic I, Surguta S, Baranyi M, Cserepes M, Tovari J
Biomed Pharmacother
. 2024 Oct;
180:117601.
PMID: 39476764
The poor vascularization of solid tumors results in oxygen-deprived areas within the tumor mass. This phenomenon is defined as tumor hypoxia and is considered to be a major contributor to...
2.
Surguta S, Baranyi M, Svajda L, Cserepes M, Randelovic I, Tatrai E, et al.
Sci Rep
. 2024 Sep;
14(1):20482.
PMID: 39227650
Lung cancer is the leading cause of cancer-related death globally. Metastasis is the most common reason of mortality in which hypoxia is suggested to have a pivotal role. However, the...
3.
Gomena J, Modena D, Cordella P, Vari B, Randelovic I, Borbely A, et al.
Eur J Med Chem
. 2024 Aug;
277:116767.
PMID: 39146832
Targeted tumour therapy has proved to be an efficient alternative to overcome the limitations of conventional chemotherapy. The upregulation of the bombesin receptor 2 (BB2) in several malignancies and the...
4.
Abranyi-Balogh P, Bajusz D, Orgovan Z, Keeley A, Petri L, Peczka N, et al.
Commun Chem
. 2024 Jul;
7(1):168.
PMID: 39085342
Fragment screening is a popular strategy of generating viable chemical starting points especially for challenging targets. Although fragments provide a better coverage of chemical space and they have typically higher...
5.
Peczka N, Randelovic I, Orgovan Z, Csorba N, Egyed A, Petri L, et al.
ACS Chem Biol
. 2024 Jul;
19(8):1743-1756.
PMID: 38991015
Covalent drugs might bear electrophiles to chemically modify their targets and have the potential to target previously undruggable proteins with high potency. Covalent binding of drug-size molecules includes a noncovalent...
6.
Tatrai E, Randelovic I, Surguta S, Tovari J
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791951
The hypoxic condition has a pivotal role in solid tumors and was shown to correlate with the poor outcome of anticancer treatments. Hypoxia contributes to tumor progression and leads to...
7.
Ludwig G, Randelovic I, Dimic D, Komazec T, Maksimovic-Ivanic D, Mijatovic S, et al.
Biomolecules
. 2024 Apr;
14(4).
PMID: 38672437
The (pentamethylcyclopentadienyl)chloridoiridium(III) complex bearing a κ,κ-bonded PhPCHCHSPh ligand ([Ir(η-CMe)Cl(PhP(CH)SPh-κκ)]PF, ()] was synthesized and characterized. Multinuclear (H, C and P) NMR spectroscopy was employed for the determination of the structure. Moreover,...
8.
Baranyi M, Hegedus B, Molnar E, Tovari J, Randelovic I, Perczel A, et al.
Magy Onkol
. 2024 Mar;
67(3):223-235.
PMID: 38484318
In silico studies raised the possibility that farnesyltransferase inhibitors (FTIs) may have antitumoral effects on KRAS mutant cancer cells. Accordingly, we have tested FTIs (tipifarnib and lonafarnib) in G12C mutant...
9.
Randelovic I, Nyiri K, Koppany G, Baranyi M, Tovari J, Kigyos A, et al.
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38473821
Mutated genes may lead to cancer development in numerous tissues. While more than 600 cancer-causing genes are known today, some of the most widespread mutations are connected to the RAS...
10.
Mezo G, Gomena J, Randelovic I, Dokus E, Kiss K, Petho L, et al.
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38339141
Chemotherapy is still one of the main therapeutic approaches in cancer therapy. Nevertheless, its poor selectivity causes severe toxic side effects that, together with the development of drug resistance in...